15 Search Results

q=Collaboration

Search Again


Shreeram Akilesh , MD, PhD

Email: shreeram@uw.edu

Phone: (206) 598-6408

Dr. Akilesh is presently applying next generation genomic tools and analyses to understand the development, structure and function of the kidney and its component cells in health and disease.

View Bio

Brittany Barber , MD, MSc, FRCSC

Email: bbarber1@uw.edu

Dr. Barber's clinical interests include head and neck cancer surgery, robotic surgery, and salivary and endocrine surgery. She has a special interest in reconstructive surgery for skin cancers. Her research interests include quality improvement in free flap reconstruction, peripheral nerve regeneration, cancer genomics, and HPV-related oropharyngeal cancer treatment.

View Bio

Susan Bullman , PhD

Email: sbullman@fredhutch.org

Phone: (206) 667-3449

The Bullman Lab focuses firstly on understanding the translational impact of the tumor microbiota in human cancers, and secondly on the delineation of specific mechanisms involved in the pathogenesis of microbe-associated human cancers. They combine molecular microbiology, computational biology, biochemistry, and genetics to understand host-microbial interactions within the tumor microenvironment. Through such efforts, her lab seeks to make discoveries that have both a scientific and clinical impact in the emerging area of bacterial-associated malignancies. Bacterial agents that have a role in cancer initiation or progression provide a viable route for prevention and treatment of these cancers.

View Bio

James Dai , PhD

Email: jdai@fredhutch.org

Phone: (206) 667-6364

James Dai’s Lab works in statistical genetics and genomics, design and analysis of randomized clinical trials, statistical methods for high-dimensional feature selection and prediction, gene-treatment interaction, mediation and instrumental variables regression. Methodologically, his lab is also interested in cancer genomics topics, for example integrative genomic analyses and intra-tumor heterogeneity. The overarching scientific interest is to discover and validate and genomic markers that drive cancer etiology, predict cancer prognosis and treatment efficacy.

View Bio

Cole DeForest , PhD

Email: ProfCole@uw.edu

Phone: (206) 543-5961

The DeForest Group seeks to integrate the governing principles of rational design with fundamental concepts from material science, synthetic chemistry, and stem cell biology to conceptualize, create, and exploit next-generation materials to address a variety of health-related problems. They are currently interested in the development of new classes of user-programmable hydrogels whose biochemical and biophysical properties can be tuned in time and space over a variety of scales. Their work relies heavily on the utilization of cytocompatible bioorthogonal chemistries, several of which can be initiated with light and thereby confined to specific sub-volumes of a sample. By recapitulating the dynamic nature of the native tissue through 4D control of the material properties, these synthetic environments are utilized to probe and better understand basic cell function as well as to engineer complex heterogeneous tissue.

View Bio

Heather Gustafson , PhD

Email: heather.gustafson@seattlechildrens.org

Phone: (206) 884-7339

Dr. Gustafson's career has focused on harnessing existing and developing novel technology platforms that alter macrophage function through environmental manipulation. Her current research, involves engineering several macrophage phenotype targeting methods in order to understand these interactions. Her lab does this through the development of technology platforms that target specific macrophage phenotypes and alter macrophage phenotypes for therapeutic and diagnostic applications. Through the development and use of these technologies they can develop and understanding of how environmental cues impact macrophage function, how macrophage function drives disease progression and how to harness that information to engineer novel technologies to treat disease.

View Bio

Yawen Li , PhD

Email: liyw@uw.edu

Phone: (206) 616-8518

Dr. Li is interested in therapeutic and diagnostic radiopharmaceuticals, astatine labeling reagents for small molecule labeling, and developing chemical methods for separation of high specific activity medical radionuclides.

View Bio

Viswam Nair , MD, MS

Email: vnair@fredhutch.org

Phone: (206) 667-4971

Dr. Viswam Nair translates fundamental scientific discoveries into the clinic to improve the care of people with lung cancer. His research focuses on biomarkers, or telltale biological markers of health or disease. He studies how to best integrate molecular and imaging-based biomarkers into clinical practice to improve lung cancer detection and treatment.

View Bio

Kayode Ojo , PhD

Email: ojo67kk@uw.edu

Phone: (206) 543-0821

The research focus of the Ojo Lab is to develop novel, robust, safe and affordable antimicrobial agents that can withstand the threat of resistance while effectively treating debilitating parasitic diseases. They also have compounds in their drug library that could have an effect on breast, lung, melanoma and prostate cancer cells.

View Bio

Amy Paguirigan , PhD

Email: apaguiri@fredhutch.org

Phone: (206) 667-4352

The focus of my research has been the integration of emerging technologies to address clinically relevant questions in cancer biology. My focus is on the interface between clinical molecular biology, bioinformatics and biotechnology, in aiming to bridge the gaps to bring novel approaches in both the biotechnological and informatics realms to clinical molecular biology to study the role of clonal diversity in cancer therapy.

View Bio

Rosana Risques , PhD

Email: rrisques@uw.edu

Phone: (206) 543-5337

Dr. Risques' research interest is the study of the genetic mechanisms that lead to tumor progression and its translation into potential biomarkers for early cancer detection. Her studies focus in ulcerative colitis, an inflammatory bowel disease that predisposes to colorectal cancer. Prior studies demonstrated that telomere shortening, mitochondrial alterations, and clonal expansions are involved in neoplastic progression in this disease. Her current efforts are dedicated to translate these molecular alterations into cancer biomarkers using novel technologies such as NanoString and new approaches to Next-Gen Sequencing.

View Bio

Frank Schmitz , MD, PhD

Email: fschmitz@fredhutch.org

Dr. Schmitz is the Director of Translational and Molecular Medicine for the Chapuis Lab at Fred Hutch. He is working on a personalized anti-tumor vaccine approach, building off previous work in innate immunity and vaccine formulation during his postdocs.

View Bio

Scott Tykodi , MD, PhD

Email: stykodi@fredhutch.org

Phone: (206) 606-7763

Dr. Tykodi treats patients with kidney cancer and melanoma. He is particularly interested in the application of immune therapies to the treatment of cancer. His research focus is in the clinical application and translational study of natural or induced T-cell immunity targeting renal cell carcinoma and other cancers.

View Bio